Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Tigermed, a China Clinical Stage CRO, Plans ChiNext IPO - FLASH: Price set

publication date: Jul 31, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Tigermed Consulting, the clinical stage CRO headquartered in Hangzhou, will stage an IPO on the ChiNext exchange. The company will offer 13.4 million A shares, which will constitute 25% of the company expanded share base. The company plans to price the offering next week on August 6. UPDATE: Pricing to be set at 37.8 RMB/share raising about $80 million US.  More details,,,,

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...